2023-06-26 12:05:01 ET
Shares of Swiss biotech Pharvaris ( NASDAQ: PHVS ) were up 13% in midday trading Monday following news that US regulators had lifted a clinical hold on testing for its proposed treatment for hereditary angioedema, or HAE.
Pharvaris said the US Food and Drug Administration has lifted a hold on its investigational new drug application, or IND, for its drug deucrictibant as an on-demand treatment for acute attacks of HAE. The company plans to request an end of Phase 2 meeting with the FDA and is preparing for a global Phase 3 study in that indication.
The company added that it expects to submit data by the end of the year to address a clinical hold on its IND for deucrictibant as a prophylactic treatment for HAE.
More on Pharvaris:
Pharvaris announces $70M private placement financing
Pharvaris adds 58% on positive data from mid-stage hereditary angioedema trial Pharvaris: Focused Pipeline On Hereditary Angioedema
For further details see:
Pharvaris stock climbs 13% after FDA lifts hold on HAE drug candidate